Phase 3 Ankylosing Spondylitis Trial, Recruiting NCT07535554 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Ankylosing Spondylitis
Back to Ankylosing Spondylitis

Phase 3 Ankylosing Spondylitis Trial, Recruiting

NCT07535554
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you have a fever of unknown cause:

  • You have been ill for more than 3 weeks
  • You have had a high temperature (above 38.3°C) on more than 3 occasions, or blood tests have shown signs of inflammation on more than 3 occasions
  • Doctors have not been able to find the cause despite standard initial tests

If you may have a condition called IgG4-related disease (IgG4-RD):

  • An experienced specialist strongly suspects you have this condition based on your symptoms, examination, and test results
  • You have recently been diagnosed with IgG4-RD through a tissue sample (biopsy) and need further scans to check how far the condition has spread
  • You have a previously confirmed diagnosis of IgG4-RD and a specialist believes it has come back

If you may have a condition causing inflammatory back pain (axial spondyloarthropathy):

  • An experienced rheumatology specialist strongly suspects you have this condition based on symptoms such as back pain lasting more than 3 months, stiffness in the morning, pain that improves with movement but worsens with rest, pain at night, and onset before age 45
  • You still have ongoing inflammatory back pain after trying 2 different types of standard anti-inflammatory painkillers (each tried for 2–4 weeks), and you are therefore being considered for a stronger type of medication called biological therapy

Who may not be able to join:

  • You are not able to fully understand the study or are unwilling or unable to take part in all required procedures
  • You have another condition or disorder that the study doctor feels could put your safety at risk or affect your ability to follow the study plan
  • You are currently receiving or have previously received a treatment that the study doctor feels could affect your safety or the reliability of the trial results
  • You are pregnant (a urine pregnancy test will be done if applicable), breastfeeding, planning to become pregnant, or you could become pregnant and are not using a reliable, highly effective form of contraception (confirm with trial site for specific accepted methods)
  • You are already taking part in another clinical trial involving an experimental medicine or device, unless the study team considers both trials to be compatible
  • You have taken part in a scientific study in the last 12 months where the experimental procedures exposed you to more than 1 mSv of radiation
  • You have a known allergy or sensitivity to the imaging agent used in this trial, called [¹⁸F]AlF-FAPI-74, or any of its ingredients
  • You have already started active treatment for the condition being studied

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +0032 16 34 37 15

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
17 September 2025
Est. completion
31 March 2029

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

FUO/IUO: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is equivalent or superior to the current gold standard, [18F] FDG PET/CT, in contributing to the final diagnosis (non-inferiority study with non-inferiority limit (10%); IgG4-RD: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is superior to [18F]FDG PET/CT, in patients with suspicion of IgG4-RD and assessment of disease extent in patients with confirmed or relapsed IgG4-RD.; Axial Spondyloarthritis: evaluate the diagnostic accuracy of [18F]AlF-FAPI-74 PET/CT in differentiating inflammatory b...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov